The second phase of testing for the mRNA vaccine will arrive in the second phase of testing next year. After this stage, as instructed by pharmaceutical companies MSD and Moderna, the vaccine will proceed to the third clinical test before being approved. The scientific name of the vaccine is Mrna-4157/v940, and it uses the same technology that was applied to the vaccine against Covid-19.
Read more: Fake news contributed to the drop in childhood vaccination numbers
see more
Japanese company imposes time restriction and reaps benefits
Alert: THIS poisonous plant landed a young man in the hospital
Recently, in the last phase added to the study, specialists tested the mRNA vaccine together with the monoclonal antibody Keytruda in patients who were being treated for skin cancer (melanoma). About 157 people participated as volunteers in the study.
Last test result
Pharmaceutical companies said the vaccine along with the antibody eased a person's risk of developing the same disease again. So far, data from the second phase of the study have not yet been released to any scientific journal.
How will the vaccine work?
As a preparation for immunity, mRNA vaccines carry the molecule that will drive cells to produce proteins in the body. These proteins will be received by the immune system, and it is through them that the body will recognize the disease and will prevent it from developing.
In addition, the vaccine has used the same technology that promoted the vaccine against Covid-19, as indicated by Stéphane Bancel, director general of Moderna.
“The use of mRNA was transformative for [immunization against] Covid-19, and now, for the first time, demonstrated the potential for mRNA to have an impact on the outcomes of a clinical trial in melanoma".
If the tests are approved, the vaccine will serve to contain other cases of oncology.
“Brazil is the second country in the world with the highest rate of skin cancer, and the combination of knowledge between the two companies combining the mRNA vaccine with immunotherapy is an innovation that can help bring great benefits to Brazilian patients”, pointed out Marcia Abadi, medical director of MSD Brazil.
Does the last test phase have a scheduled date?
The results of the tests carried out so far have shown positive aspects of the vaccine against cancer. It is expected that by 2023 the three main phases for vaccine approval will already be completed.
However, before the third phase, it will be necessary for the Food and Drug Administration (FDA) to release the endorsement in the USA or Anvisa (National Health Surveillance Agency) to release it in Brazil.
Lover of movies and series and everything that involves cinema. An active curious on the networks, always connected to information about the web.